$6.24 (+7.03%) | As of Aug-15-2025 📸 

🎬 Trigger Event: Lights, Camera, Insider Action!

Insiders are back in the Kodak booth buying up shares like it’s 1999.

• 👔 Jim Continenza (CEO & Executive Chairman): grabbed 50,000 shares @ $5.74 (+$287K). He now owns almost 1.9M shares. Commitment, or desperation? You decide.

• 🎩 Philippe Katz (Director, 10% holder): keeps adding too, scooping up 10,000 shares @ $5.67 (+$56.7K). He’s already sitting on 4.4M shares.

• Others have dabbled before, but the latest moves feel like “we either print money or get printed in bankruptcy court.”

👀 Insider ownership is already 41% (that’s high). Institutions like Vanguard and BlackRock are in too, but only hold 46%, meaning they’re still cautious about this nostalgia-fueled rollercoaster.

🔍 For Kodak (KODK)'s Institutional Ownership breakdown, see here. 

🏭 What Kodak Actually Does in 2025 (Yes, It Still Exists)

Forget the disposable cameras — Kodak today is a mashup of:

• 📚 Print biz: plates, presses, software, and inks (PROSPER Turbo Press still sounds like a Mario Kart upgrade).

• ⚗️ Advanced Materials & Chemicals (AM&C): film, chemicals, IP licensing, plus… 🧪 new pharma manufacturing. Yup, Kodak pivoted from pictures to pills.

• ©️ Brand licensing: letting “Kodak” be slapped on random stuff.

And yes, they still own Eastman Business Park in Rochester, NY — a kind of industrial coworking space for science nerds.

💰 Financials: Snapshot in Harsh Lighting

Q2 2025:

• 📉 Revenue: $263M (down 1% YoY)

• 🩸 Gross profit: $51M (down 12%)

• 💔 Net loss: -$26M (vs +$26M profit last year 😬)

• ⚠️ Cash: $155M (shrinking fast; was $201M at YE 2024)

• 🔥 Operating EBITDA: $9M (down 25%)

FY 2024:

• Revenues: $1.04B (down 7%)

• Net income: +$102M (yay last year!)

• Operating EBITDA: $26M (down 42%)

• Cash: $201M (down from $255M)

In short: 📉 shrinking sales + ⚠️ cash burn = Kodak moment of truth.

👉 Want the full picture? Dive into Kodak (KODK)'s financials here.

🚑 Kodak’s “New Script” — Pharma Pivot

Here’s the real plot twist:

• 📜 Kodak now has an FDA-certified pharmaceutical manufacturing facility.

• First product: phosphate buffered saline (PBS) (aka salty water for labs 🧂💧).

• Future ambition: injectable IV saline & more high-margin regulated pharma.

Could Kodak become less of a faded photography relic and more of a specialty pharma supplier? Possibly. But it’s a bold bet.

📊 Valuation Polaroid

Cheap, but…

• 📸 Price/Sales: 0.52 (super low, “dollar-store” cheap).

• 📸 Price/Book: 0.95 (undervalued on paper).

• 📸 P/E: 9.11 trailing (but forward P/E is broken because… losses).

• Debt: $500M+ looming, Debt/EBITDA ~3x, and…

🚨 Going concern warning: Kodak literally disclosed it may not be able to survive without refinancing or using pension cash. Ouch.

🎭 The Good, the Bad & the Ugly

✅ The Good

• CEO & Director insiders are buying.

• Pharma pivot could be transformative.

• Stock is dirt cheap vs sales/book.

❌ The Bad

• Revenues shrinking.

• Cash burn accelerating.

• Huge debt load with no guaranteed financing.

☠️ The Ugly

• “Going concern” warning in SEC filing. Translation: 🚨 “We might not make it.”

• Share price is still a fraction of where it was 10+ years ago.

💡💡💡 Curious about another deep oil exploration play?
Check our takes on UnitedHealth Group or even Oscar Health.

🎯 Bottom Line

Eastman Kodak is like your old film camera: dusty, unreliable, but with a certain vintage charm 📸.

• Best-case: Kodak reinvents itself as a profitable pharma/chemicals play while insiders look like geniuses. 🚀

• Worst-case: debt eats the company alive and shareholders get left with nothing but nostalgia. 🪦

Verdict: High risk. High (maybe) reward. But right now? More speculative lottery ticket than safe investment. Buy only if you like thrill rides. 🎢

🚨 Disclaimer:

We don’t sell cameras or pills. We laugh, we analyze, we meme — we’re not licensed advisors and we do not provide investment advice. We just sell jokes and opinions — and yes, we’re billing your sense of humor. 🎪💸 
We’re not financial advisors. We’re FUNancial advisors. 
Invest at your own risk, always DYOR, hold the FOMO, and don’t invest what you can’t afford to lose.

🧭 Want More Like This?

• 🕵️ Insider Purchases Center
• 📣 Follow the Pundits Hub
• 📈 Young Guns & Turnaround Stocks — Track More Growth (and Growing-Pain) Plays
• 😆 Stock Market Humor & Serious-ish Plays
• 🌍 See the world differently and check out more international market picks and fun takes. Explore International Investment Opportunities and value plays 💸 Cheap Stocks with (Maybe) Big Upside
• 🧟 Corporate Resurrection Series — Our special series on companies rising from the financial grave. 🎯 The “Turnaround or Toast” Series (If it still exists. We’re not sure. Ask the intern.)
• 📈 Biotech Bets & Innovation Radar (Problem is we can't detect the Radar)

😂 Laugh, Learn, Invest: funanc1al.com | Funanc1al: Where Even Finance Meets Funny